Talphera (TLPH) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 03, 2021
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		119,102,999

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	[1]
Current Assets:
Cash and cash equivalents	$ 34,363	$ 27,274
Short-term investments	32,982	15,612
Accounts receivable, net	658	635
Inventories, net	1,419	1,626
Prepaid expenses and other current assets	1,893	1,683
Total current assets	71,315	46,830
Operating lease right-of-use assets	312	3,150
Property and equipment, net	15,650	15,659
Other assets	70	656
Total Assets	87,347	66,295
Current Liabilities:
Accounts payable	3,235	2,737
Accrued liabilities	3,245	4,890
Long-term debt, current portion	8,749	8,735
Deferred revenue, current portion	0	49
Operating lease liabilities, current portion	283	1,118
Liability related to the sale of future royalties, current portion	32	106
Total current liabilities	15,544	17,635
Long-term debt, net of current portion	11,265	13,140
Operating lease liabilities, net of current portion	72	2,606
Liability related to the sale of future royalties, net of current portion	87,597	88,365
Other long-term liabilities	181	299
Total liabilities	114,659	122,045
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value—200,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 119,102,999 and 98,812,008 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	118	98
Additional paid-in capital	420,011	382,637
Accumulated deficit	(447,441)	(438,485)
Total stockholders’ deficit	(27,312)	(55,750)
Total Liabilities and Stockholders’ Deficit	$ 87,347	$ 66,295
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	119,102,999	98,812,008
Common stock, shares outstanding (in shares)	119,102,999	98,812,008

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Revenue	$ 511	$ 386
Operating costs and expenses:
Cost of goods sold	1,040	1,511
Research and development	969	1,412
Selling, general and administrative	7,644	13,311
Total operating costs and expenses	9,653	16,234
Loss from operations	(9,142)	(15,848)
Other income (expense):
Interest expense	(672)	(855)
Interest income and other income (expense), net	76	(65)
Non-cash interest income on liability related to future sale of royalties	782	843
Total other income (expense)	186	(77)
Net loss	(8,956)	(15,925)
Comprehensive loss	$ (8,956)	$ (15,925)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.08)	$ (0.20)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 10 (in shares)	113,256,550	80,057,405
Product [Member]
Revenue:
Revenue	$ 451	$ 274
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 60	$ 112

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' (Deficit) Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	79,573,101
Balance at Dec. 31, 2019	$ 79	$ 356,609	$ (398,106)	$ (41,418)
Stock-based compensation		1,146		1,146
Restricted stock units vested (in shares)	216,399
Tax payments related to shares withheld for restricted stock units vested		(86)		(86)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	431,800
Net proceeds from issuance of common stock in connection with equity financings	$ 1	783		784
Issuance of common stock upon ESPP purchase (in shares)	194,451
Issuance of common stock upon ESPP purchase		218		218
Net loss			(15,925)	(15,925)
Balance (in shares) at Mar. 01, 2020	80,415,751
Balance at Mar. 01, 2020	$ 80	358,670	(414,031)	(55,281)
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	382,637	(438,485)	(55,750)	[1]
Stock-based compensation		1,089		1,089
Restricted stock units vested (in shares)	404,172
Tax payments related to shares withheld for restricted stock units vested		(249)		(249)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	19,701,562
Net proceeds from issuance of common stock in connection with equity financings	$ 20	36,340		36,360
Issuance of common stock upon ESPP purchase (in shares)	183,132
Issuance of common stock upon ESPP purchase		192		192
Issuance of common stock upon exercise of stock options (in shares)	2,125
Issuance of common stock upon exercise of stock options		2		2
Net loss			(8,956)	(8,956)
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	$ 420,011	$ (447,441)	$ (27,312)
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		66 Months Ended
	Mar. 01, 2020	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (15,925)	$ (8,956)	$ (15,925)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization		(45)	(84)
Non-cash interest income on liability related to royalty monetization		(782)	(843)	$ 27,443
Depreciation and amortization		450	487
Non-cash interest expense related to debt financing		222	271
Stock-based compensation		1,089	1,146
Gain on lease termination		(522)	0
Other		68	111
Changes in operating assets and liabilities:
Accounts receivable		(23)	(135)
Inventories		105	88
Prepaid expenses and other assets		361	461
Accounts payable		313	1,528
Accrued liabilities		(1,698)	(1,209)
Operating lease liabilities		(241)	(181)
Deferred revenue		(49)	(79)
Net cash used in operating activities		(9,708)	(14,364)
Cash flows from investing activities:
Purchase of property and equipment		(24)	(73)
Purchase of investments		(24,441)	(12,757)
Proceeds from maturities of investments		7,040	35,480
Net cash (used in) provided by investing activities		(17,425)	22,650
Cash flows from financing activities:
Payment of long-term debt		(2,083)	0
Net proceeds from issuance of common stock in connection with equity financings		36,360	784
Net proceeds from issuance of common stock through equity plans		194	218
Payment of employee tax obligations related to vesting of restricted stock units		(249)	(86)
Net cash provided by financing activities		34,222	916
Net increase in cash and cash equivalents		7,089	9,202
Cash and cash equivalents—Beginning of period	$ 14,684	27,274	14,684
Cash and cash equivalents—End of period		$ 34,363	$ 23,886	$ 34,363

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one not May 12, 2021 ( Termination of Gr nenthal Agreements The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. Although Zalviso was approved for sale in Europe on September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7 Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2021, not may December 31, 2021. December 31, 2020, December 31, 2020, 10 10 December 31, 2020, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2020. no three March 31, 2021, 2020 10 Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents and short-term investments (in thousands): As of March 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 3,643 $ — $ — $ 3,643 Money market funds 12,523 — — 12,523 Commercial paper 18,197 — — 18,197 Total cash and cash equivalents 34,363 — — 34,363 Short-term investments: U.S. government agency securities 2,751 — — 2,751 Commercial paper 27,179 — — 27,179 Corporate debt securities 3,052 — — 3,052 Total short-term investments 32,982 — — 32,982 Total cash, cash equivalents and short-term investments $ 67,345 $ — $ — $ 67,345 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886 There were no March 31, 2021 December 31, 2020. no three March 31, 2021 2020. As of March 31, 2021, December 31, 2020, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third March 31, 2021, December 31, 2020, 5 two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of March 31, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 12,523 $ 12,523 $ — $ — U.S. government agency securities 2,751 — 2,751 — Commercial paper 45,376 — 45,376 — Corporate debt securities 3,052 — 3,052 — Total assets measured at fair value $ 63,702 $ 12,523 $ 51,179 $ — Liabilities Contingent put option liability $ 181 $ — $ — $ 181 Total liabilities measured at fair value $ 181 $ — $ — $ 181 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three March 31, 2021 2020 Three Months Ended March 31, 2021 Fair value—beginning of period $ 246 Change in fair value of contingent put option associated with the Loan Agreement (65 ) Fair value—end of period $ 181 Three Months Ended March 31, 2020 Fair value—beginning of period $ 437 Change in fair value of contingent put option associated with the Loan Agreement 309 Fair value—end of period $ 746

Note 3 - Inventories, Net

Note 3 - Inventories, Net	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of March 31, 2021 December 31, 2020 Raw materials $ 161 $ 257 Work-in-process — 30 Finished goods 1,258 1,339 Total $ 1,419 $ 1,626 The Company recorded inventory impairment charges of $0.1 million, primarily related to Zalviso component parts inventory, for the three March 31, 2021, may three March 31, 2020.

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4. The following table summarizes revenue from contracts with customers for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Product sales: DSUVIA $ 181 $ 155 Zalviso 270 119 Total product sales 451 274 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 45 84 Royalty revenue 15 28 Total revenues from contract and other collaboration 60 112 Total revenue $ 511 $ 386 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2020. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. May 12, 2021. Contract and Other Collaboration Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe. Contract Liability The following table presents changes in the Company’s contract liability for the three March 31, 2021 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Grünenthal Agreements $ 49 $ — $ (49 ) $ — Deferred revenue $ 49 $ — $ (49 ) $ — For the three March 31, 2021 2020, Three Month Ended March 31, 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 49 $ 79 New activities in the period from performance obligations satisfied: Performance obligations satisfied 221 40 Total revenue from performance obligations satisfied or eliminated $ 270 $ 119

Note 5 - Long-term Debt

Note 5 - Long-term Debt	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	5. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. In connection with the Loan Agreement, on May 30, 2019, As of March 31, 2021, three March 31, 2021, three March 31, 2020. Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. March 31, 2021, March 31, 2021

Note 6 - Leases

Note 6 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	6. The Company leases office and laboratory space for its corporate headquarters, located at 301 351 On March 26, 2021, April 30, 2021. three March 31, 2021. April 30, 2021, On March 26, 2021, 25821 April 1, 2021. two three one March 31, 2021, March 31, 2021. The components of lease expense are presented in the following table (in thousands): Three Months Ended March 31, 2021 2020 Operating lease costs $ 340 $ 340 Gain on derecognition of operating lease (522 ) — Sublease income (150 ) (150 ) Net lease costs $ (332 ) $ 190 The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: March 31, 2021 Weighted-average remaining term – operating lease (in years) 0.57 Weighted-average discount rate – operating lease 12.03 % Future minimum lease payments as of March 31, 2021 Year: 2021 (remaining nine months) $ 309 2022 100 Total future minimum lease payments 409 Less imputed interest (54 ) Total $ 355 Reported as: Operating lease liabilities $ 283 Operating lease liabilities, net of current portion 72 Total lease liability $ 355 Future minimum sublease payments as of March 31, 2021 Year: 2021 (remaining nine months) $ 51 Total future minimum sublease payments $ 51

Note 7 - Liability Related to S

Note 7 - Liability Related to Sale of Future Royalties	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	7. In September 2015, first four 80% The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the three June 30, 2020, November 13, 2020. May 12, 2021 May 12, 2021. may The effective interest rate over the life of the liability will be 0% as we record interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for each of the three March 31, 2021 2020, The following table shows the activity within the liability account for the three March 31, 2021 ( Three months ended March 31, 2021 Period from inception to March 31, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (60 ) (998 ) Non-cash interest (income) expense recognized (782 ) 27,443 Liability related to sale of future royalties as of March 31, 2021 87,629 87,629 Less: current portion (32 ) (32 ) Liability related to sale of future royalties — net of current portion $ 87,597 $ 87,597 As royalties are remitted to SWK from ARPI LLC, as described in Note 1 10 December 31, 2020,

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Equity Common Stock Underwritten Public Offering On January 22, 2021, January 27, 2021, ATM Agreement The Company has entered into a Controlled Equity Offering SM may During the three March 31, 2021, three March 31, 2020, March 31, 2021, may

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	9. The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended 2011 Three Months Ended March 31, 2021 2020 Cost of goods sold $ 22 $ 46 Research and development 181 200 Selling, general and administrative 886 900 Total $ 1,089 $ 1,146 As of March 31, 2021,

Note 10 - Net Loss Per Share of

Note 10 - Net Loss Per Share of Common Stock	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	10. The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: March 31, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,789,212 15,630,340 Common stock warrants 176,679 176,679

Note 11 - Subsequent Event

Note 11 - Subsequent Event	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	11. On April 21, 2021, March 31, 2021, 30 The term of the CSA is for a period of five first two one 24 The Company will pay Catalent an annual fee beginning on the first 10 December 31, 2022, may January 1 January 1, 2023,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 January 2006, AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one not May 12, 2021 ( Termination of Gr nenthal Agreements The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. Although Zalviso was approved for sale in Europe on September 18, 2015, August 31, 2020, third DSUVIA/DZUVEO DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 June 2018, DSUVIA was approved with a Risk Evaluation and Mitigation Strategy, or REMS, which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not Zalviso Zalviso delivers 15 September 2013 July 25, 2014. IAP312, IAP312 August 2017, three 3 Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 7
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain prior period amounts in the Condensed Consolidated Financial Statements have been reclassified to conform to the current period's presentation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2021, not may December 31, 2021. December 31, 2020, December 31, 2020, 10 10 December 31, 2020,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. not

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of March 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 3,643 $ — $ — $ 3,643 Money market funds 12,523 — — 12,523 Commercial paper 18,197 — — 18,197 Total cash and cash equivalents 34,363 — — 34,363 Short-term investments: U.S. government agency securities 2,751 — — 2,751 Commercial paper 27,179 — — 27,179 Corporate debt securities 3,052 — — 3,052 Total short-term investments 32,982 — — 32,982 Total cash, cash equivalents and short-term investments $ 67,345 $ — $ — $ 67,345 As of December 31, 2020 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 5,181 $ — $ — $ 5,181 Money market funds 3,996 — — 3,996 Commercial paper 18,097 — — 18,097 Total cash and cash equivalents 27,274 — — 27,274 Short-term investments: U.S. government agency securities 5,818 — — 5,818 Commercial paper 9,794 — — 9,794 Total short-term investments 15,612 — — 15,612 Total cash, cash equivalents and short-term investments $ 42,886 $ — $ — $ 42,886
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of March 31, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 12,523 $ 12,523 $ — $ — U.S. government agency securities 2,751 — 2,751 — Commercial paper 45,376 — 45,376 — Corporate debt securities 3,052 — 3,052 — Total assets measured at fair value $ 63,702 $ 12,523 $ 51,179 $ — Liabilities Contingent put option liability $ 181 $ — $ — $ 181 Total liabilities measured at fair value $ 181 $ — $ — $ 181 As of December 31, 2020 Fair Value Level I Level II Level III Assets Money market funds $ 3,996 $ 3,996 $ — $ — U.S. government agency securities 5,818 — 5,818 — Commercial paper 27,891 — 27,891 — Total assets measured at fair value $ 37,705 $ 3,996 $ 33,709 $ — Liabilities Contingent put option liability $ 246 $ — $ — $ 246 Total liabilities measured at fair value $ 246 $ — $ — $ 246
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended March 31, 2021 Fair value—beginning of period $ 246 Change in fair value of contingent put option associated with the Loan Agreement (65 ) Fair value—end of period $ 181 Three Months Ended March 31, 2020 Fair value—beginning of period $ 437 Change in fair value of contingent put option associated with the Loan Agreement 309 Fair value—end of period $ 746

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of March 31, 2021 December 31, 2020 Raw materials $ 161 $ 257 Work-in-process — 30 Finished goods 1,258 1,339 Total $ 1,419 $ 1,626

Note 4 - Revenue From Contrac_2

Note 4 - Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2021 2020 Product sales: DSUVIA $ 181 $ 155 Zalviso 270 119 Total product sales 451 274 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 7) 45 84 Royalty revenue 15 28 Total revenues from contract and other collaboration 60 112 Total revenue $ 511 $ 386
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period Contract liability: Deferred revenue – Grünenthal Agreements $ 49 $ — $ (49 ) $ — Deferred revenue $ 49 $ — $ (49 ) $ — Three Month Ended March 31, 2021 2020 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 49 $ 79 New activities in the period from performance obligations satisfied: Performance obligations satisfied 221 40 Total revenue from performance obligations satisfied or eliminated $ 270 $ 119

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended March 31, 2021 2020 Operating lease costs $ 340 $ 340 Gain on derecognition of operating lease (522 ) — Sublease income (150 ) (150 ) Net lease costs $ (332 ) $ 190 March 31, 2021 Weighted-average remaining term – operating lease (in years) 0.57 Weighted-average discount rate – operating lease 12.03 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2021 (remaining nine months) $ 309 2022 100 Total future minimum lease payments 409 Less imputed interest (54 ) Total $ 355 Operating lease liabilities $ 283 Operating lease liabilities, net of current portion 72 Total lease liability $ 355
Lessee, Operating Sublease, to Be Received, Maturity [Table Text Block]	Year: 2021 (remaining nine months) $ 51 Total future minimum sublease payments $ 51

Note 7 - Liability Related to_2

Note 7 - Liability Related to Sale of Future Royalties (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Other Liabilities [Table Text Block]	Three months ended March 31, 2021 Period from inception to March 31, 2021 Liability related to sale of future royalties — beginning balance $ 88,471 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue (60 ) (998 ) Non-cash interest (income) expense recognized (782 ) 27,443 Liability related to sale of future royalties as of March 31, 2021 87,629 87,629 Less: current portion (32 ) (32 ) Liability related to sale of future royalties — net of current portion $ 87,597 $ 87,597

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2021 2020 Cost of goods sold $ 22 $ 46 Research and development 181 200 Selling, general and administrative 886 900 Total $ 1,089 $ 1,146

Note 10 - Net Loss Per Share _2

Note 10 - Net Loss Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	March 31, 2021 2020 ESPP, RSUs and stock options to purchase common stock 16,789,212 15,630,340 Common stock warrants 176,679 176,679

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Debt Securities, Available-for-sale, Realized Gain (Loss), Total	$ 0	$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Amortized Cost	$ 67,345	$ 42,886
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	67,345	42,886
Cash and Cash Equivalents [Member]
Amortized Cost	34,363	27,274
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	34,363	27,274
Cash and Cash Equivalents [Member] | Cash [Member]
Amortized Cost	3,643	5,181
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	3,643	5,181
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Amortized Cost	12,523	3,996
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	12,523	3,996
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Amortized Cost	18,197	18,097
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	18,197	18,097
Cash and Cash Equivalents [Member] | U.S. Government Agency Securities [Member]
Amortized Cost		5,818
Gross Unrealized Gains		0
Gross Unrealized Losses		0
Fair Value		5,818
Marketable Securities [Member]
Amortized Cost	32,982	15,612
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	32,982	15,612
Marketable Securities [Member] | Commercial Paper [Member]
Amortized Cost	27,179	9,794
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	27,179	$ 9,794
Marketable Securities [Member] | U.S. Government Agency Securities [Member]
Amortized Cost	2,751
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	2,751
Marketable Securities [Member] | Corporate Debt Securities [Member]
Amortized Cost	3,052
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Fair Value	$ 3,052

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Assets, fair value	$ 63,702	$ 37,705
Liabilities, fair value	181	246
Contingent Put Option Liability [Member]
Liabilities, fair value	181	246
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	12,523	3,996
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	51,179	33,709
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	181	246
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	181	246
Money Market Funds [Member]
Assets, fair value	12,523	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	12,523	3,996
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member]
Assets, fair value	2,751	5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	2,751	5,818
U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	45,376	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	45,376	27,891
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	$ 0
Corporate Debt Securities [Member]
Assets, fair value	3,052
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	3,052
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair value, Beginning of period	$ 246	$ 437
Change in fair value of contingent put option associated with the Loan Agreement	(65)
Change in fair value of contingent put option associated with the Loan Agreement		309
Fair value, End of period	$ 181	$ 746

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
ZALVISO [Member]
Inventory Write-down	$ 0.1
DSUVIA [Member]
Inventory Write-down		$ 0.1

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Raw materials	$ 161	$ 257
Work-in-process	0	30
Finished goods	1,258	1,339
Total	$ 1,419	$ 1,626	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 4 - Revenue From Contrac_3

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 511	$ 386
DSUVIA [Member]
Revenue	181	155
ZALVISO [Member]
Revenue	270	119
Product [Member]
Revenue	451	274
Non-cash Royalty [Member]
Revenue	45	84
Royalty [Member]
Revenue	15	28
Contract and Other Collaboration [Member]
Revenue	$ 60	$ 112

Note 4 - Revenue From Contrac_4

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Contract Liabilities: Deferred Revenue	$ 49
Contract Liabilities: Deferred Revenue, Additions	0
Contract Liabilities: Deferred Revenue, Deductions	(49)
Contract Liabilities: Deferred Revenue	0
Revenue	511	$ 386
ZALVISO [Member]
Contract Liabilities: Deferred Revenue	49
Contract Liabilities: Deferred Revenue, Additions	0
Contract Liabilities: Deferred Revenue, Deductions	(49)
Contract Liabilities: Deferred Revenue	0
Revenue	270	119
Amended License Agreement [Member]
Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied	49	79
New activities in the period from performance obligations satisfied: Performance obligations satisfied	221	40
Revenue	$ 270	$ 119

Note 5 - Long-term Debt (Detail

Note 5 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2019	Mar. 31, 2021	Mar. 31, 2020	May 30, 2019
Amortization of Debt Discount (Premium)		$ 222	$ 271
Leasehold Improvements [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total		1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement		$ 900
Debt Instrument, Interest Rate, Effective Percentage		14.35%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount				$ 25,000
Long-term Debt, Total		$ 19,100
Interest Expense, Debt, Total		600	800
Amortization of Debt Discount (Premium)		$ 200	$ 200

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual) - USD ($)	Mar. 26, 2021	Mar. 31, 2021	Mar. 31, 2020	Feb. 16, 2019
Percentage of Office and Laboratory Space Sublease				47.00%
Gain (Loss) on Termination of Lease	$ 500,000	$ 522,000	$ 0
Lease for Corporate Headquarters in Hayward, California [Member]
Lessee, Operating Lease, Term of Contract (Year)	2 years 3 months
Lessee, Operating Lease, Monthly Rent	$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)	1 month
Prepaid Expenses and Other Current Assets [Member]
Lessee, Operating Sublease, Deferred Costs		300,000
Prepaid Expenses and Other Current Assets [Member] | Lease for Corporate Headquarters in Hayward, California [Member]
Prepaid Rent		$ 100,000

Note 6 - Leases - Operating Lea

Note 6 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	Mar. 26, 2021	Mar. 31, 2021	Mar. 31, 2020
Operating lease costs		$ 340	$ 340
Gain on derecognition of operating lease	$ (500)	(522)	0
Sublease income		(150)	(150)
Net lease costs		$ (332)	$ 190
Weighted-average remaining term – operating lease (in years) (Year)		6 months 25 days
Weighted-average discount rate – operating lease		12.03%

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	[1]
2021 (remaining nine months)	$ 309
2022	100
Total future minimum lease payments	409
Less imputed interest	(54)
Total	355
Operating lease liabilities	283	$ 1,118
Operating lease liabilities, net of current portion	72	$ 2,606
Total lease liability	$ 355
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 6 - Leases - Future Minimu

Note 6 - Leases - Future Minimum Sublease Payments (Details) $ in Thousands	Mar. 31, 2021USD ($)
2021 (remaining nine months), sublease	$ 51
Total future minimum sublease payments, sublease	$ 51

Note 7 - Liability Related to_3

Note 7 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	Sep. 18, 2015	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020
Proceeds From Sale of Royalty and Milestone Rights	$ 65
Royalty Arrangment Maximum Payments	$ 195
Contingent Gain (Loss) on Royalty Monetization Arrangement			$ 65
Effective Interest Over Life of Liability Related to Sale of Future Royalties					0.00%
Effective Annual Interest Rate		3.60%		3.60%
PDL [Member]
Percentage of Royalties and Rights Under Agreement	75.00%
PDL [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement	80.00%
Commercial Milestones Value Maximum Amount Available	$ 35.6
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available	$ 44.5

Note 7 - Liability Related to_4

Note 7 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	3 Months Ended		66 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	[1]
Liability related to sale of future royalties — beginning balance	$ 88,471		$ 0
Proceeds from sale of future royalties	0		61,184
Non-cash royalty revenue	(60)		(998)
Non-cash interest (income) expense recognized	(782)	$ (843)	27,443
Liability related to sale of future royalties as of March 31, 2021	87,629		87,629
Less: current portion	(32)		(32)	$ (106)
Liability related to sale of future royalties — net of current portion	$ 87,597		$ 87,597	$ 88,365
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jan. 27, 2021	Jan. 27, 2021	Jan. 22, 2021	May 09, 2019	Mar. 31, 2021	Mar. 31, 2020
Proceeds from Issuance of Common Stock					$ 36,360	$ 784
Private Placement [Member] | Armistice Capital and Rock Springs Capital [Member]
Stock Issued During Period, Shares, New Issues (in shares)	16,675,000	2,175,000	14,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 1.7625	$ 1.7625	$ 1.7625
Proceeds from Issuance of Common Stock	$ 28,900
ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)					3,000,000	431,800
Aggregate Offering Price, Maximum				$ 80,000	$ 36,100
Proceeds from Issuance of Common Stock, Net					$ 7,500	$ 800

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - The 2020 Equity Incentive Plan [Member]	Mar. 31, 2021shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	7,882,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	14,839,543
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)	1,666,529

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation expense	$ 1,089	$ 1,146
Cost of Sales [Member]
Stock-based compensation expense	22	46
Research and Development Expense [Member]
Stock-based compensation expense	181	200
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 886	$ 900

Note 10 - Net Loss Per Share _3

Note 10 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	16,789,212	15,630,340
Warrant [Member]
Antidilutive securities (in shares)	176,679	176,679

Note 11 - Subsequent Event (Det

Note 11 - Subsequent Event (Details Textual) - Subsequent Event [Member] - Catalent Pharma Solutions [Member]	Apr. 21, 2021
Commercial Supply Agreement, Term (Year)	5 years
Commercial Supply Agreement, Extended Term (Year)	2 years